Barclays’s Takeda Pharmaceutical TAK Stock Holding History

Barclays’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-150,000	Closed	-$2.74M	–	5070
2021 Q1	$2.74M	Sell	150,000 -62,830	-30%	-$1.13M	﹤0.01%	2023
2020 Q4	$3.87M	Hold	212,830	–	–	﹤0.01%	1700
2020 Q3	$3.8M	Hold	212,830	–	–	﹤0.01%	1591
2020 Q2	$3.82M	Sell	212,830 -70,388	-25%	-$1.26M	﹤0.01%	1572
2020 Q1	$4.3M	Sell	283,218 -12,499	-4%	-$227K	﹤0.01%	1596
2019 Q4	$5.83M	Sell	295,717 -300	-0.1%	-$5.74K	﹤0.01%	1849
2019 Q3	$5.09M	Buy	296,017 +596	+0.2%	+$10.3K	﹤0.01%	1837
2019 Q2	$5.23M	Buy	295,421 +25,414	+9%	+$462K	﹤0.01%	1827
2019 Q1	$5.5M	Buy	+270,007	New	+$5.43M	﹤0.01%	1592

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays's TAK Position: Q1 2026 in Review

Barclays reduced its Takeda Pharmaceutical (TAK) stake by 90% in Q1 2026, selling an estimated $191K and leaving 1,241 shares worth $23K. The position accounts for ﹤0.01% of the portfolio, ranked #4552.

Barclays first reported a position in TAK in Q4 2018 and has held it in 30 quarters since. The position peaked at $27.9M in Q1 2023. 358 funds tracked by Wall St. Rank hold TAK as of Q1 2026.

Barclays held 1,241 shares of Takeda Pharmaceutical worth $23K as of Q1 2026.
Barclays sold 10,896 Takeda Pharmaceutical shares in Q1 2026, an estimated $191K.
Takeda Pharmaceutical made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4552 holding.
Barclays first reported a position in Takeda Pharmaceutical in Q4 2018 and has held it in 30 quarters since.
Barclays's Takeda Pharmaceutical position peaked at $27.9M in Q1 2023.
358 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.